加载中
NASDAQHealthcareMedical - Devices
最新数据
US$0.7922
−US$0.0317 · -3.85%
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.
前收盘价
US$0.7922
−US$0.0317 · -3.85%
盘后
US$0.7817
−US$0.0105 · -1.33%
10月12日 19:20 ET
盘中时间采用ET。市场数据可能有所延迟。
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.
日内区间
当前US$0.7922
52周区间
当前US$0.7922
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
45
合理估值
情绪
56
多空交织
风险
67
高风险
动量
19
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.
日内区间
当前US$0.7922
52周区间
当前US$0.7922
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | 24.9万 USD | — |
| 销货成本 | — | — | — | 20.01万 USD | — |
| 毛利 | — | — | — | 4.89万 USD | — |
| 研究与开发 | 304.64万 USD | 347.17万 USD | 571.46万 USD | 415.22万 USD | 114.8万 USD |
| 销售、一般及管理费用 | 390.65万 USD | 369.79万 USD | 459.66万 USD | 521.45万 USD | 208.22万 USD |
| 营业费用 | 695.3万 USD | 716.96万 USD | 1031.12万 USD | 936.67万 USD | 323.02万 USD |
| 利息收入 | 9.76万 USD | 14.58万 USD | 16.49万 USD | 8.97万 USD | 51.33万 USD |
| 利息支出 | 839 USD | 82.3万 USD | — | — | 36.75万 USD |
| 折旧和摊销 | 17.07万 USD | 19.91万 USD | 78.1万 USD | 30.64万 USD | 14.57万 USD |
| 营业利润 | −695.3万 USD | −716.96万 USD | −1031.12万 USD | −931.78万 USD | −323.02万 USD |
| 净利润 | −684.85万 USD | −771.78万 USD | −995.39万 USD | −929.69万 USD | −372.97万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年1月29日 | 1:4 | — | — |
股票拆分 | 2024年11月18日 | 1:50 | — | — |
股票拆分 | 2024年6月20日 | 1:8 | — | — |
股票拆分 | 2023年7月24日 | 1:20 | — | — |
已生效 2026年1月29日
1:4
已生效 2024年11月18日
1:50
已生效 2024年6月20日
1:8
已生效 2023年7月24日
1:20
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
